LaserEnNCT04979156
LaserEn: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
StatusUnknown
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Notable Primary and study completion dates pushed to Dec 31, 2024v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Aug 1, 2021 to Nov 4, 2021
- Study sites: 0 to 1
- Minor Study description shortened, about 225 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
To determine the ability to obtain identifiable pathologic characteristics of bladder tumor specimens by use the SOLTIVE™ laser during en bloc resection.
Timeframe: 6 months
Secondary (3)
To evaluate the overall recurrence rate as well as the recurrence rate at the prior resection site after SOLTIVE™ en bloc resection of bladder tumors.
To evaluate patient symptoms before and after en bloc tumor resection
• To evaluate short-term complications within 3 months after SOLTIVE™ en bloc resection of bladder tumors.
Arms and interventions
SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
Procedures: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
Sites
1 site in 1 country
- University of Kansas Medical CenterKansas City, Kansas, United States